All Articles by Author:

Noshin Noorjahan

LIMK2 Inactivation Suppresses Mechanical Stimulation-Induced Dermal Fibroblast Differentiation and Resistance to Apoptosis

[Scientific Reports] Researchers investigated the role of LIMK2, a component of the Rho/ROCK/LIMK/cofilin pathway, in cell differentiation and apoptosis in response to mechanical stimulation and proliferation in human dermal fibroblasts.

An Update on the Landscape of Collagen Bioactive Fragments

[FEBS Journal] Investigators provide an overview of the latest findings describing the roles of major bioactive fragments from collagens I, IV, VI, and XVIII in various physiological and pathological contexts affecting heart, lung, adipose, and even brain tissues.

Cell Adhesion Molecules As Emerging Regulators of Ferroptosis: Mechanisms and Therapeutic Opportunities in Cancer

[Apoptosis] The authors offer a systematic summary of the roles played by major cell adhesion molecules families—namely, the immunoglobulin superfamily, cadherins, and integrins—in the regulation of ferroptosis.

FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia

[FibroBiologics, Inc.] FibroBiologics, Inc. announced that the Canadian Intellectual Property Office has issued Canadian Patent No. 3118732, titled “Treatment of Cachexia Using Fibroblast Cells and Products Thereof.”

Human Subcutaneous Derived Stromal Vascular Fraction Endothelial Cells Display Venous and Arterial Markers in Culture and 3D Capillaries

[Tissue Engineering and Regenerative Medicine] Researchers investigated endothelial cells from the stromal vascular fraction of human subcutaneous white adipose tissue in 2D culture and 3D bioengineered skin models to better define their specific subtypes.

Ethanol Alters DNMT1/3a/3b Expression Profile, Promotes Persistent DNA Hypomethylation in Human Brain Endothelial Cells, and Impairs Late Cortical Angiogenesis

[Journal of Neurochemistry] Scientists investigated whether ethanol-induced effects on endothelial cells involve epigenetic reprogramming, specifically through alterations in DNA methylation profiles.

Popular

Innovative CAR-T Cell Therapy Receives FDA Breakthrough Therapy Designation

[Washington University] A cell-based immunotherapy developed by Washington University researchers has been granted Breakthrough Therapy designation by the US FDA.

The University of Colorado Anschutz Gates Institute Achieves First-in-US FDA Clearance for Campus-Built CAR T-Cell Therapy

[University of Colorado (CU) Anschutz] The University of Colorado Anschutz Gates Institute has received Investigational New Drug clearance from the US FDA, marking the first CAR-T cell therapy authorized for clinical testing that was developed entirely on the CU Anschutz campus.

AvenCell Therapeutics Announces First Patient Dosed in Phase I QUADvance Study with AVC-203, a Novel Allogeneic CD19/CD20 Dual-Targeting CAR-T Investigational Therapy for the Treatment...

[AvenCell Therapeutics, Inc.] AvenCell Therapeutics, Inc. announced that it has dosed the first patient in the Phase I QUADvance study with AVC-203 for the treatment of relapsed/refractory B cell malignancies.